UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate

Annals of neurology, 2012-09, Vol.72 (3), p.385-394

2012

Volltextzugriff (PDF)

The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation

Immunity (Cambridge, Mass.), 2021-02, Vol.54 (2), p.308-323.e6

2021

Volltextzugriff (PDF)

Ana Sotrel, MDFebruary 10, 1943 — May 22, 2022

Journal of neuropathology and experimental neurology, 2022-09, Vol.81 (9), p.765-765

2022

Volltextzugriff (PDF)

Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis

Frontiers in immunology, 2016-11, Vol.7, p.543-543

2016

Volltextzugriff (PDF)

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes

The Journal of immunology (1950), 2008-05, Vol.180 (10), p.6988-6996

2008

Volltextzugriff (PDF)

Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis

Human brain mapping, 2013-12, Vol.34 (12), p.3376-3391

2013

Volltextzugriff (PDF)

STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways

The Journal of immunology (1950), 2021-05, Vol.206 (9), p.2015-2028

2021

Volltextzugriff (PDF)

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

The Lancet (British edition), 2004-05, Vol.363 (9421), p.1607-1608

2004

Volltextzugriff (PDF)

Simvastatin inhibits secretion of Th17‐polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis

European journal of immunology, 2013-01, Vol.43 (1), p.281-289

2013

Volltextzugriff (PDF)

Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study

Frontiers in rehabilitation sciences, 2022-01, Vol.2, p.795306-795306

2022

Volltextzugriff (PDF)

IFN-β1a Inhibits the Secretion of Th17-Polarizing Cytokines in Human Dendritic Cells via TLR7 Up-Regulation

The Journal of immunology (1950), 2009-03, Vol.182 (6), p.3928-3936

2009

Volltextzugriff (PDF)

Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein

Human molecular genetics, 2003-04, Vol.12 (7), p.749-757

2003

Volltextzugriff (PDF)

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis

Therapeutic advances in neurological disorders, 2015-03, Vol.8 (2), p.59-70

2015

Volltextzugriff (PDF)

Humanized Anti-CD25 (Daclizumab) Inhibits Disease Activity in Multiple Sclerosis Patients Failing to Respond to Interferon β

Proceedings of the National Academy of Sciences - PNAS, 2004-06, Vol.101 (23), p.8705-8708

2004

Volltextzugriff (PDF)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Neurology and therapy, 2024-04, Vol.13 (2), p.283-322

2024

Volltextzugriff (PDF)

Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder

Journal of neuroimmunology, 2015-01, Vol.278, p.108-111

2015

Volltextzugriff (PDF)

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study

PloS one, 2014-03, Vol.9 (3), p.e91098-e91098

2014

Volltextzugriff (PDF)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

BMC neurology, 2015-11, Vol.15 (232), p.232-232, Article 232

2015

Volltextzugriff (PDF)

A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases

Self/nonself, 2011-01, Vol.2 (1), p.35-42

2011

Volltextzugriff (PDF)

Simvastatin inhibits secretion of T h17‐polarizing cytokines and antigen presentation by DC s in patients with relapsing remitting multiple sclerosis

European journal of immunology, 2013-01, Vol.43 (1), p.281-289

2013

Volltextzugriff (PDF)

Functional HLA-DM on the surface of B cells and immature dendritic cells

The EMBO journal, 2000-03, Vol.19 (6), p.1241-1251

2000

Volltextzugriff (PDF)

T cell LFA-1 engagement induces HuR-dependent cytokine mRNA stabilization through a Vav-1, Rac1/2, p38MAPK and MKK3 signaling cascade

PloS one, 2010-12, Vol.5 (12), p.e14450-e14450

2010

Volltextzugriff (PDF)

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1829-1839

2012

Volltextzugriff (PDF)

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis

Endocrine, metabolic & immune disorders drug targets, 2010-06, Vol.10 (2), p.161-167

2010

Volltextzugriff (PDF)

Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: Implications for the initiation of the autoimmune response in multiple sclerosis

European journal of immunology, 2008-05, Vol.38 (5), p.1297-1309

2008

Volltextzugriff (PDF)

1 – 25 von 114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(113)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(54)
Humans
(51)
Immunology
(33)
Multiple Sclerosis
(32)
Female
(26)
Adult
(21)
Male
(20)
Middle Aged
(20)
Neurosciences & Neurology
(20)
Neurology
(19)
Multiple Sclerosis - Immunology
(15)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(15)
Multiple Sclerosis, Relapsing-Remitting - Immunology
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(13)
Cd4-Positive T-Lymphocytes - Immunology
(12)
Clinical Neurology
(12)
Neurosciences
(12)
Animals
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate

The TGF-β superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation

Ana Sotrel, MDFebruary 10, 1943 — May 22, 2022

Activated IL-1RI Signaling Pathway Induces Th17 Cell Differentiation via Interferon Regulatory Factor 4 Signaling in Patients with Relapsing-Remitting Multiple Sclerosis

Simvastatin Inhibits IL-17 Secretion by Targeting Multiple IL-17-Regulatory Cytokines and by Inhibiting the Expression of IL-17 Transcription Factor RORC in CD4+ Lymphocytes

Diffusion tensor imaging based network analysis detects alterations of neuroconnectivity in patients with clinically early relapsing-remitting multiple sclerosis

STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

Simvastatin inhibits secretion of Th17‐polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis

Dalfampridine for Mobility Limitations in People With Multiple Sclerosis May Be Augmented by Physical Therapy: A Non-randomized Two-Group Proof-of-Concept Pilot Study

IFN-β1a Inhibits the Secretion of Th17-Polarizing Cytokines in Human Dendritic Cells via TLR7 Up-Regulation

Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein

A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing–remitting multiple sclerosis

Humanized Anti-CD25 (Daclizumab) Inhibits Disease Activity in Multiple Sclerosis Patients Failing to Respond to Interferon β

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives

Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial

A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases

Simvastatin inhibits secretion of T h17‐polarizing cytokines and antigen presentation by DC s in patients with relapsing remitting multiple sclerosis

Functional HLA-DM on the surface of B cells and immature dendritic cells

T cell LFA-1 engagement induces HuR-dependent cytokine mRNA stabilization through a Vav-1, Rac1/2, p38MAPK and MKK3 signaling cascade

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis

Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: Implications for the initiation of the autoimmune response in multiple sclerosis

Suchergebnisse filtern